argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$43.6b

argenx Management

Management criteria checks 4/4

argenx's CEO is Tim Van Hauwermeiren, appointed in Apr 2008, has a tenure of 17.42 years. total yearly compensation is $7.81M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $13.46M. The average tenure of the management team and the board of directors is 3.6 years and 7.3 years respectively.

Key information

Tim Van Hauwermeiren

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage9.70%
CEO tenure17.4yrs
CEO ownership0.03%
Management average tenure3.6yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin

Jun 30

Argenx: The Magic May Be Already Priced In

Mar 24

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

CEO Compensation Analysis

How has Tim Van Hauwermeiren's remuneration changed compared to argenx's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

US$1b

Mar 31 2025n/an/a

US$1b

Dec 31 2024US$8mUS$758k

US$833m

Sep 30 2024n/an/a

-US$40m

Jun 30 2024n/an/a

-US$204m

Mar 31 2024n/an/a

-US$328m

Dec 31 2023US$12mUS$656k

-US$295m

Sep 30 2023n/an/a

-US$234m

Jun 30 2023n/an/a

-US$397m

Mar 31 2023n/an/a

-US$511m

Dec 31 2022US$8mUS$639k

-US$710m

Sep 30 2022n/an/a

-US$909m

Jun 30 2022n/an/a

-US$907m

Mar 31 2022n/an/a

-US$595m

Dec 31 2021US$7mUS$652k

-US$408m

Sep 30 2021n/an/a

-US$373m

Jun 30 2021n/an/a

-US$319m

Mar 31 2021n/an/a

-US$573m

Dec 31 2020US$9mUS$641k

-US$608m

Sep 30 2020n/an/a

-US$535m

Jun 30 2020n/an/a

-US$359m

Mar 31 2020n/an/a

-US$275m

Dec 31 2019US$7mUS$589k

-US$181m

Sep 30 2019n/an/a

-US$109m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$47m

Dec 31 2018US$5mUS$573k

-US$76m

Compensation vs Market: Tim's total compensation ($USD7.81M) is below average for companies of similar size in the US market ($USD13.61M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.

CEO

Tim Van Hauwermeiren (53 yo)

17.4yrs
Tenure
US$7,807,786
Compensation

Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, serves as Independent Non-Executive Director of Lexeo Therapeutics, Inc since July 2024. He had been Independent Director at iTeos Therapeutics,...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
Co-Founder17.4yrsUS$7.81m0.031%
$ 13.5m
Karl Gubitz
Chief Financial Officer4.3yrsUS$5.27m0.00082%
$ 357.1k
Karen Massey
Chief Operating Officer2.5yrsUS$6.19mno data
Peter Ulrichts
Chief Scientific Officer2.7yrsno datano data
Malini Moorthy
General Counsel3.6yrsno data0%
$ 0
Arjen Lemmen
Vice President of Corporate Development & Strategy6.3yrsno datano data
Andria Wilk
Global Head of Quality5.7yrsno datano data
Luc Truyen
Chief Medical Officer3.4yrsno datano data
Filip Borgions
Chief Technology Innovation Officer3.4yrsno datano data
Beth DelGiacco
VP and Global Head of Corporate Communications & Investor Relations3.4yrsno datano data
Marc Schorpion
Global Head of Human Resources6.8yrsno datano data
3.6yrs
Average Tenure
53yo
Average Age

Experienced Management: ARGX's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
Co-Founder11.2yrsUS$7.81m0.031%
$ 13.5m
Peter K. Verhaeghe
Independent Chairman of the Board11.2yrsUS$592.23k0.0032%
$ 1.4m
Anthony Rosenberg
Independent Vice Chairman8.4yrsUS$557.23k0.0032%
$ 1.4m
Brian Kotzin
Non-Executive Director1.3yrsUS$765.66kno data
James Daly
Independent Non-Executive Director7.3yrsUS$567.23k0.0032%
$ 1.4m
Pamela M. Klein
Independent Non-Executive Director9.4yrsUS$544.73k0.0032%
$ 1.4m
Hans de Haard
Member of Board Advisorsno datano datano data
David Lacey
Member of Board Advisorsno dataUS$622.58kno data
Steve Krognes
Independent Non-Executive Director2.6yrsUS$559.73k0.0022%
$ 945.1k
Camilla Sylvest
Independent Non-Executive Director3yrsUS$544.73k0.0027%
$ 1.2m
Wim Parys
Member of Board Advisorsno datano datano data
Ana Cespedes
Independent Non-Executive Director2.8yrsUS$544.73k0.0019%
$ 836.2k
7.3yrs
Average Tenure
64.5yo
Average Age

Experienced Board: ARGX's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/03 14:12
End of Day Share Price 2025/09/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 55 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird